International consensus guidance for management of myasthenia gravis: 2020 update
Objective To update the 2016 formal consensus-based guidance for the management of
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …
Complement in human disease: approved and up-and-coming therapeutics
The complement system is recognised as a protector against blood-borne pathogens and a
controller of immune system and tissue homoeostasis. However, dysregulated complement …
controller of immune system and tissue homoeostasis. However, dysregulated complement …
Complement in neurological disorders and emerging complement-targeted therapeutics
The complement system consists of a network of plasma and membrane proteins that
modulate tissue homeostasis and contribute to immune surveillance by interacting with the …
modulate tissue homeostasis and contribute to immune surveillance by interacting with the …
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders
JJGM Verschuuren, J Palace, H Murai… - The Lancet …, 2022 - thelancet.com
Summary Myasthenia gravis and Lambert-Eaton myasthenic syndrome are antibody-
mediated autoimmune diseases of the neuromuscular junction that usually present with …
mediated autoimmune diseases of the neuromuscular junction that usually present with …
New therapies for neuromyelitis optica spectrum disorder
M Levy, K Fujihara, J Palace - The Lancet Neurology, 2021 - thelancet.com
Background Neuromyelitis optica spectrum disorder is an autoimmune disease of the CNS
that primarily affects the optic nerves and spinal cord. Most patients have serum antibodies …
that primarily affects the optic nerves and spinal cord. Most patients have serum antibodies …
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 …
Introduction Ravulizumab demonstrated efficacy and an acceptable safety profile versus
placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in …
placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in …
Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a …
Importance Many patients with generalized myasthenia gravis (gMG) have substantial
clinical disability, persistent disease burden, and adverse effects attributable to chronic …
clinical disability, persistent disease burden, and adverse effects attributable to chronic …
Current treatment of myasthenia gravis
MK Alhaidar, S Abumurad, B Soliven… - Journal of clinical …, 2022 - mdpi.com
Myasthenia gravis (MG) is the most extensively studied antibody-mediated disease in
humans. Substantial progress has been made in the treatment of MG in the last century …
humans. Substantial progress has been made in the treatment of MG in the last century …
Novel immunotherapies for myasthenia gravis
Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy
centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and …
centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and …
Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture
I Koneczny, R Herbst - Cells, 2019 - mdpi.com
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction (NMJ).
Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor …
Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor …